Heartsciences Inc. Reports Minimal Revenues for Q3 2025; Research and Development Expenses Decrease by 19% Compared to Q3 2024
Heartsciences Inc. has released its financial results for the quarter ending July 31, 2025. The company reported revenues of $2,000, an increase from zero in the same period last year. The cost of sales for the quarter was $1,000, resulting in a gross margin of $1,000. Operating expenses decreased by 10% to $1.874 million from $2.076 million in the previous year. This includes a 19% decrease in research and development expenses to $997,000 and a 3% increase in selling, general, and administrative expenses to $878,000. Consequently, the company reported a reduced loss from operations of $1.874 million compared to a loss of $2.076 million in the same quarter last year. The company did not provide any specific outlook or guidance for the future period within the report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001468492-25-000010), on September 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。